

June 5, 2015



# Doug Janzen Appointed Chairman of Perimeter Medical Imaging

Perimeter Medical Imaging Inc., a developer of real time imaging systems for in-surgery tumor margin assessment, today named Doug Janzen as Chairman of the Board.

Mr Janzen is the Founder and President of NorthView Ventures, an entity which invests in and provides strategic advisory services to a number of technology companies. Prior to that, he was President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that raised over \$300M from investors and completed over \$1Billion in licensing deals during his tenure. In 2010 Cardiome's lead product Brinavess was approved and launched in Europe by Merck. Prior to that, Mr. Janzen was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences. Mr. Janzen is a past winner of Vancouver's Top 40 under 40 award, is the past Chairman of Life Sciences British Columbia, has served as a Director of Biotech Canada and sits as a Director on a number of public and private boards.

"Doug's 20 years of healthcare management experience in strategic advisory, funding and operational leadership roles has already provided extremely valuable perspective to Perimeter's Board of Directors. He has been instrumental in the early formation of the company and I appreciate his willingness to take on Chairman responsibilities," said Paul Weber, President and CEO. "I look forward to continuing to benefit from his strong judgment and counsel."

Mr Janzen commented, "I've worked with the Perimeter leadership team in previous ventures and was pleased to be involved in the early stages of Perimeter. The team has done an amazing job on exceeding all milestones and I am excited by future prospects. We have an opportunity to really make an impact on the quality of patient care."

## About Perimeter Medical Imaging Inc.

Perimeter Medical develops, patents, and commercializes advanced surgical imaging tools that allow surgeons, radiologists and pathologists to better assess microscopic tissue structures during the surgical procedure. Perimeter's OTI<sup>SM</sup> is the only solution that provides clinicians with an ultra high resolution image of the entire surface of the removed tissue specimen, providing accurate information in real time, enabling better decisions and ultimately reducing the need for follow-on 2nd surgeries. Perimeter is a privately owned Canadian company. For more information, visit [www.perimetermed.com](http://www.perimetermed.com).

## Media Contact

Paul Weber, President and CEO  
Perimeter Medical Imaging Inc.

(647) 504-4260

[pweber@perimetermed.com](mailto:pweber@perimetermed.com)

\*CAUTION - OTIS is an investigational device limited by Federal (or United States) law to investigational use.